UC: infliximab beats golimumab in comparison of trial data

  • Singh S & al.
  • Clin Gastroenterol Hepatol
  • 17 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • For moderate-to-severe ulcerative colitis (UC), this post hoc analysis suggests that more patients achieve remission with infliximab (Remicade; Janssen Biotech) and do so more quickly than with golimumab (Simponi; Janssen Biotech).

Why this matters

  • Head-to-head trials comparing treatment options for moderate-to-severe UC are lacking.
  • Among the TNF-α antagonists, network meta-analysis has suggested infliximab may work better.

Study design

  • Post hoc analysis of individual patient data from phase 3 ACT-1, ACT-2, and PURSUIT-SC trials comparing standard-dose infliximab and golimumab, available through Yale Open Database Access (YODA; n=1793).
  • Authors adjusted extensively for patient-level covariates.
  • Outcome: patient-reported outcome 2 remission (PRO2, composite of rectal bleeding score of 0 and stool frequency score ≤1 at week 2); clinical remission (Mayo Clinic Score
  • Funding: NIH.

Key results

  • Infliximab vs golimumab:
    • PRO2: 35.0% vs 30.0%; aOR, 1.71 (95% CI, 1.15-2.55).
    • PRO at week 6: 50.0% vs 38.9%; aOR, 2.03 (1.40-2.94).
    • Clinical remission: aOR, 3.01 (1.95-4.70).

Limitations

  • Proof would require head-to-head comparison study.
  • Comparison applies only to induction, not maintenance.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit